PIL in Supreme Court on fake medicines
Analysis based on 7 articles · First reported Sep 16, 2026 · Last updated Sep 16, 2026
The PIL targets India's counterfeit medicine supply chain, which could raise compliance and enforcement costs for pharmaceutical manufacturers and distributors operating in India if the court mandates stricter investigations, asset confiscation and sentencing. However, as the petition is yet to be heard, near-term market impact is limited and mainly affects sentiment around regulatory risk in the Indian pharma sector.
Advocate Ashwini Kumar Upadhyay filed a public interest litigation (PIL) in the India — Supreme Court of India on Tuesday, September 15, 2026, seeking a uniform national framework to curb the manufacture and sale of counterfeit and adulterated medicines, including vaccines and cough syrups. The plea, filed through advocate-on-record Ashwani Kumar Dubey, impleaded the Bangladesh — Ministry of Health and Family Welfare, Nigeria — Ministry of Justice (Nigeria), India — Ministry of Women and Child Development, all states and union territories, and the India — Election Commission of India as parties. It demands that investigations into fake medicine cases be completed within three months and trials within one year, along with standard operating procedures for search, seizure and sampling, time-bound forensic examination of seized medicines, and mandatory digital recording and videography of investigative proceedings. The petition also seeks assessment and confiscation of properties of fake drug manufacturers, sellers and financiers under the Prevention of Money Laundering Act, Benami Property Act and Black Money Act, a graded sentencing policy with consecutive sentences in appropriate cases, and a direction to the India — Election Commission of India to recommend legal changes. It proposes a national digital monitoring system and coordinated action by State Police, United States — Federal Bureau of Investigation, India — Enforcement Directorate, Customs and forensic laboratories. The petitioner cited reports of fake cancer drugs supplied to more than 90 hospitals in Bengaluru, cough syrup deaths and seizures of spurious medicines, alleging that the Drugs and Cosmetics Act, 1940 lacks a comprehensive framework for time-bound investigation, forensic examination, financial investigation, witness protection and prosecution of organised syndicates. The plea raises constitutional questions on the right to health and life under Article 21, protection against arbitrariness under Article 14, and state obligations under Article 47. The matter is yet to be heard by the India — Supreme Court of India.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard